MedTrace Logo

Gene Therapy and Ganciclovir in Treating Patients With Stage IV Melanoma

NCT00005057 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL

Last updated 2015-04-29

No results posted yet for this study

Summary

RATIONALE: Inserting a modified herpesvirus gene into a person's melanoma cells may make the cancer more sensitive to the antiviral agent ganciclovir.

PURPOSE: Phase I trial to study the effectiveness of gene therapy in treating patients who have stage IV melanoma.

Conditions

  • Melanoma (Skin)

Interventions

BIOLOGICAL

adenovirus RSV-TK

DRUG

ganciclovir

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    collaborator NIH

  • National Human Genome Research Institute (NHGRI)

    lead NIH

Principal Investigators

  • John C. Morris, MD · NCI - Metabolism Branch;MET

Study Design

Purpose
TREATMENT

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2000-03-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00005057 on ClinicalTrials.gov